The biology of erbB-2/neu/HER-2 and its role in cancer - PubMed (original) (raw)

Review

The biology of erbB-2/neu/HER-2 and its role in cancer

N E Hynes et al. Biochim Biophys Acta. 1994.

No abstract available

PubMed Disclaimer

Similar articles

• Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase.
  Stancovski I, Sela M, Yarden Y. Stancovski I, et al. Cancer Treat Res. 1994;71:161-91. doi: 10.1007/978-1-4615-2592-9_9. Cancer Treat Res. 1994. PMID: 7946947 Review. No abstract available.
• HER2/neu expression in cancer: the pathologist as diagnostician or prophet?
  Foster CS, Gosden CM, Ke Y. Foster CS, et al. Hum Pathol. 2003 Jul;34(7):635-8. doi: 10.1016/s0046-8177(03)00357-5. Hum Pathol. 2003. PMID: 12874757 Review. No abstract available.
• The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.
  Ross JS, Fletcher JA. Ross JS, et al. Semin Cancer Biol. 1999 Apr;9(2):125-38. doi: 10.1006/scbi.1998.0083. Semin Cancer Biol. 1999. PMID: 10202134 Review.
• Basic science of HER-2/neu: a review.
  Hung MC, Lau YK. Hung MC, et al. Semin Oncol. 1999 Aug;26(4 Suppl 12):51-9. Semin Oncol. 1999. PMID: 10482194 Review.
• HER-2/neu receptor gene status in endometrial carcinomas: a tissue microarray study.
  Xu M, Schwartz P, Rutherford T, Azodi M, Santin A, Silasi D, Martel M, Hui P. Xu M, et al. Histopathology. 2010 Jan;56(2):269-73. doi: 10.1111/j.1365-2559.2009.03464.x. Histopathology. 2010. PMID: 20102407 No abstract available.

Cited by

• A Novel HER2 Protein Identification Methodology in Breast Cancer Cells Using Raman Spectroscopy and Raman Imaging: An Analytical Validation Study.
  Abramczyk H, Surmacki JM, Kopeć M. Abramczyk H, et al. J Med Chem. 2024 Oct 10;67(19):17629-17639. doi: 10.1021/acs.jmedchem.4c01591. Epub 2024 Sep 21. J Med Chem. 2024. PMID: 39305290 Free PMC article.
• The Evolving Paradigm of Antibody-Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases.
  High P, Guernsey C, Subramanian S, Jacob J, Carmon KS. High P, et al. Pharmaceutics. 2024 Jul 2;16(7):890. doi: 10.3390/pharmaceutics16070890. Pharmaceutics. 2024. PMID: 39065587 Free PMC article. Review.
• Antibody-drug conjugates in gastric cancer: from molecular landscape to clinical strategies.
  Hao JL, Li XY, Liu YT, Lang JX, Liu DJ, Zhang CD. Hao JL, et al. Gastric Cancer. 2024 Sep;27(5):887-906. doi: 10.1007/s10120-024-01529-y. Epub 2024 Jul 4. Gastric Cancer. 2024. PMID: 38963593 Review.
• BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436.
  Teufelsbauer M, Stickler S, Eggerstorfer MT, Hammond DC, Hamilton G. Teufelsbauer M, et al. Breast Cancer Res Treat. 2024 Nov;208(1):89-101. doi: 10.1007/s10549-024-07403-w. Epub 2024 Jun 19. Breast Cancer Res Treat. 2024. PMID: 38896334 Free PMC article.
• HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review.
  Pan L, Li J, Xu Q, Gao Z, Yang M, Wu X, Li X. Pan L, et al. Medicine (Baltimore). 2024 Jun 14;103(24):e38508. doi: 10.1097/MD.0000000000038508. Medicine (Baltimore). 2024. PMID: 38875362 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal